Valion Bio, formerly Tivic Health Systems, reported its first quarter results under the new name, highlighting advances in its Entolimod immunotherapeutic platform and deeper engagement with U.S. government agencies for radiation syndrome countermeasures. The company also progressed the integration of its manufacturing subsidiary, Velocity Bioworks, which supports both internal drug production and third-party biotech clients. Financially, operating expenses rose due to acquisition and development costs, with a net loss of $6.2 million for Q1 2026. Valion Bio is focused on advancing Entolimod toward FDA approval and expanding applications of its next-generation molecule, Entolasta, especially in oncology supportive care.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
Standard Chartered has partnered with Broadcom to modernize its global banking infrastructure by adopting a secure, resilient private cloud using VMware Cloud Foundation. This upgrade supports critical banking services across 54 markets with enhanced...
